CYP2E1 and metabolic dysfunction-associated steatotic liver disease: The genetic deletion and/or inhibition of CYP2E1 was shown to prevent/reduce hepatic steatosis in AFLD and NAFLD models16, 17, 22, 23, 24, which was mainly attributed to the development of nitroxidative stress and in some cases the alteration of proteins involved in lipid homeostasis such as PPAR-α22, 23, 24.